drugset / Trial / NCT00002495

SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease

NCT00002495 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without doxorubicin and vinblastine in treating patients with stage I or stage II Hodgkin's disease.

Timeline

Start
1992-09
Primary completion
2000-11
Completion
2014-04

Outcome

Met primary endpoint

paper markedly superior failure-free survival (FFS) rate for patients on the CMT arm (94%) compared with the STLI arm (81%). PMID 11709567 ↗

paper 10 patients have experienced relapse or died on the chemoradiotherapy arm, compared with 34 on the radiotherapy arm (P <.001). PMID 11709567 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 25 mg/m2 —
Subject Vinblastine Small molecule 6 mg/m2 —

Indications